A Phase 2, Open-Label Study to Evaluate Efficacy of Combination Treatment With MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients With Recurrent/Metastatic Human Papilloma Virus Associated Cancers
Phase of Trial: Phase II
Latest Information Update: 27 Dec 2018
At a glance
- Drugs Durvalumab (Primary) ; MEDI 0457 (Primary)
- Indications Anal cancer; Cervical cancer; Human papillomavirus infections; Penile cancer; Vulvovaginal cancer
- Focus Therapeutic Use
- 17 Dec 2018 Parallel assignment has changed to single group. Number of arms has been reduced.
- 17 Dec 2018 Planned End Date changed from 1 Jan 2020 to 31 Jan 2020.
- 17 Dec 2018 Planned primary completion date changed from 1 Jan 2020 to 31 Jan 2020.